Business Context and Reporting Period
Envoy Medical, Inc. (Nasdaq: COCH) filed a Current Report on Form 8-K dated April 15, 2026. The filing reports a corporate governance event involving the appointment of a new director and the expansion of the Board of Directors.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed relates to executive compensation: the new director was granted stock options to purchase 100,000 shares at an exercise price of $0.72 per share.
Material Changes
- Board Expansion: The Board of Directors increased in size from six to seven members.
- Director Appointment: Charles S. McKhann was appointed as a Class I director, with a term expiring at the 2027 annual meeting.
- Committee Assignment: Mr. McKhann was appointed to the Compensation Committee.
Management Commentary and Risks
Management highlighted Mr. McKhann's extensive background in the medical device sector, including prior leadership roles at Silk Road Medical, Apollo Endosurgery, ROX Medical, Torax Medical, and Intersect ENT. The Board determined that Mr. McKhann meets the independence criteria for the Nasdaq Capital Market and the Compensation Committee. No specific risks, contingencies, or unusual items were disclosed in this filing.
Investor Verification Checklist
- Verify the vesting schedule of the 100,000 stock options granted to Mr. McKhann (36 monthly installments).
- Confirm the independence status of the new director relative to the Compensation Committee.
- Review the standard indemnification agreement referenced as Exhibit 10.21.
- Check for any subsequent filings regarding the impact of the Board expansion on corporate governance policies.